Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ABEO | US
-0.02
-0.37%
Healthcare
Biotechnology
30/06/2024
16/04/2026
5.38
5.40
5.43
5.29
Abeona Therapeutics Inc. a clinical-stage biopharmaceutical company develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101 an autologous engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York New York.
View LessPositive Momentum
Low Debt to Asset (< 0.2)
High Short-term Volatility
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
47.2%1 month
48.7%3 months
45.4%6 months
55.7%-
-
3.99
0.32
0.17
-0.58
53.29
-
-54.75M
233.03M
233.03M
-
-
-
-100.00
-127.38
11.83
6.35
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.94
Range1M
1.22
Range3M
1.46
Rel. volume
0.33
Price X volume
2.46M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Verastem Inc | VSTM | Biotechnology | 6.34 | 255.15M | 0.16% | n/a | 104.63% |
| Alector Inc | ALEC | Biotechnology | 2.55 | 248.17M | -1.16% | n/a | 23.98% |
| Northwest Biotherapeutics Inc | NWBO | Biotechnology | 0.1971 | 247.02M | -1.45% | n/a | 0.00% |
| Prelude Therapeutics Incorporated | PRLD | Biotechnology | 4.43 | 243.76M | -19.75% | n/a | 9.99% |
| Arcturus Therapeutics Ltd | ARCT | Biotechnology | 8.84 | 239.05M | 2.55% | n/a | 11.94% |
| BioAtla Inc. | BCAB | Biotechnology | 4.91 | 237.33M | 8.99% | n/a | 5.30% |
| Anika Therapeutics Inc | ANIK | Biotechnology | 15.39 | 227.72M | 0.72% | n/a | 13.35% |
| LogicBio Therapeutics Inc | LOGC | Biotechnology | 8.5 | 223.33M | -3.41% | n/a | 0.00% |
| Lexeo Therapeutics Inc. Common Stock | LXEO | Biotechnology | 6.58 | 217.54M | -3.24% | n/a | 6.58% |
| Voyager Therapeutics Inc | VYGR | Biotechnology | 3.96 | 215.95M | -1.74% | 29.89 | 13.99% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CPI Card Group Inc | PMTS | Building Products & Equipment | 17.89 | 199.61M | 1.02% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 9.74 | 156.39M | 0.72% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.99 | 100.48M | 0.63% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.12 | 99.69M | 0.49% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.93 | 74.70M | 1.14% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.32 | 59.96M | 0.00% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 14 | 21.32M | 2.04% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.612 | 11.83M | -2.84% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.74 | 10.81M | 6.52% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.335 | 3.41M | -2.06% | n/a | 17.32% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.58 | - | Cheaper |
| Ent. to Revenue | 53.29 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.99 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 45.43 | - | Lower Risk |
| Debt to Equity | 0.32 | -1.23 | Expensive |
| Debt to Assets | 0.17 | 0.25 | Cheaper |
| Market Cap | 233.03M | - | Emerging |